Evotec SE (OTCPK:EVOTF) Q2 2023 Earnings Conference Call August 29, 2023 8:00 AM ET

Company Participants

Werner Lanthaler - CEO

Laetitia Rouxel - CFO

Cord Dohrmann - CSO

Matthias Evers - Chief Business Officer

Conference Call Participants

Peter Verdult - Citigroup

James Quigley - Morgan Stanley

Wolf Chanoff - Bank of America

Steven Mah - TD Cowen

Joseph Hedden - Rx Securities

Charles Weston - RBC Capital Markets

Douglas Tsao - H.C. Wainwright

Operator

Ladies and gentlemen, thank you for standing by. Welcome and thank you for joining the Evotec SE half-year report 2023. Throughout today's recorded presentation, all participants will be in a listen-only mode. The presentation will be followed by a question-and-answer session. 9Operator instructions].

I would now like to turn the conference over to Werner Lanthaler, CEO. Please go ahead.

Werner Lanthaler

Thank you very much. Welcome to all of you. Welcome to our half-year presentation, first half of 2023. Emerging stronger, that's the theme that we have given this presentation, which will become very clear throughout presentation why we choose this topic. We have uploaded a presentation and invite you to follow this presentation, throughout this presentation, which I will give, together with my management team who is here with me. Here is Laetitia, our CFO. Here is Cord, our CSO. Here is our Chief Business Officer, Matthias, and we have to apologize, Craig, this time, is on a customer visit. I'm very happy to have my whole team around here because you see that all efforts coming together at Evotec are efforts of teams. We are strong as a team. We go through crisis as a team, and we emerge stronger as teams.

And if you go to page number five of your presentation, let me directly bring you into the highlights, and also some of the lowlights of the first half of 2023. You see that in a year where Q2 was heavily incidented by the cyberattack, we nevertheless grew by more than 14% in 2023. There are not many companies who can talk about double-digit growth in general, and definitely there are not many companies who can talk about 30% growth, which we show in Q1 of 2023. This is of course all driven by fantastic collaborations that we have closed in 2022, but also at the beginning of 2023 that are now running forward. Let me mention a few of them. Our collaboration with Janssen, our collaboration with BMS, expanded and extended in neurodegeneration, and of course a strong progress of our ongoing protein degradation partnerships with BMS. And you will see later in this presentation, the continued validation of Just-Evotec Biologics and multiple agreements that we have signed that have carried over from 2022 and are enlarged and expanded in 2023. So, you see highlights are coming together from many fronts, but also let me highlight that our pipeline-building efforts will gain traction visibility in the next couple of months. And you have seen a first highlight here with, for example, a transition and a highly attractive indication in kidney disease together with Bayer. Of course, you've heard about our lowlight of the year already enough, so let me skip this and go forward into the future because that's what's all about.